GLOBAL INDUSTRY ANALYSIS
Forecast Period 2026–2035
Pharmaceutical Stability & Storage Services Market Biologics, cryogenic capacity and outsourcing push a USD 2.05 billion market toward USD 4.05 billion USD 4.05 billion by 2035
$2.05B
$4.05B
7.1%
$1.86B
Market size, 2025
Forecast, 2035
CAGR, 2026–2035
Absolute $ opportunity
Executive Summary • North America leads with ~41% revenue share (USD 0.85B, 2025); Asia-Pacific grows fastest at 10.0% CAGR. • Stability Testing Services dominate offerings with ~44% share (USD 0.90B, 2025). • Cryogenic Storage (15.8% CAGR) and Advanced Therapies (12.6% CAGR) are the structural growth engines. • Integrated providers with cGMP chamber networks are winning bundled testing-storage-regulatory contracts.
Copyright © Next Move Strategy Consulting
01
MARKET LANDSCAPE
A USD 2.05B market set to nearly double by 2035 2035 $2.05B
$2.19B
$4.05B
7.1%
Valuation, 2025
Estimate, 2026
Forecast, 2035
CAGR, 2026–2035
Global Revenue Forecast (USD Billion)
Milestone year Forecast year 4.05 3.79 3.54
2.05
2025
2.35
2.19
2026
2027
2.51
2028
2.88
2.69
2029
2030
Leading Segment Shares, 2025
3.09
2031
3.31
2032
2033
2034
2035
Key Insights
Small Molecules (Molecule Class)
55%
• Revenue nearly doubles from USD 2.05B (2025) to USD 4.05B (2035), adding a USD 1.86B absolute opportunity.
Pharmaceutical Companies (Customer)
46%
Stability Testing Services (Offering)
44%
• The U.S. alone generated ~USD 0.70B in 2025, anchoring North America's lead. • Contract Revenue is the largest revenue model (~36%); ICH
North America (Region)
41%
Controlled Room Temp. (Temperature)
38%
Standards frame ~38% of demand. • Landscape is moderately consolidated; integrated cGMP networks gain over standalone labs.
Industry Ecosystem — Value Chain Drug Materials & Packaging
›
Stability Testing & Analytics
›
Storage Equipment & Chambers
›
Quality & Regulatory Compliance
›
Cold-Chain Logistics & Depots
›
Clinical, Commercial & Lifecycle
NMSC ANALYST VIEW
Sponsors increasingly bundle stability testing, storage and regulatory documentation into single dedicated-capacity agreements — favouring integrated providers as biologics and advanced therapy pipelines expand.
Copyright © Next Move Strategy Consulting
02
GROWTH DRIVERS & OPPORTUNITIES
Biologics, cryogenics and outsourcing set the pace the pace Impact on CAGR — Drivers vs. Restraints
Driver Restraint
Biologics & advanced therapy pipelines
+1.9%
Outsourcing of stability testing & storage
+1.6%
Regulatory complexity (ICH, FDA, national)
+1.3%
Cryogenic & cold chain infrastructure investment
+1.2%
Clinical trial globalization & depot complexity
+1.0%
Real-time environmental monitoring demand
+0.8%
High capex of cGMP chamber infrastructure
−1.2%
Peak biologics testing capacity constraints
−0.8%
Fragmented national regulatory requirements
−0.6%
Strategic Opportunities
High-Growth Segments (CAGR 2026–35)
Cryogenic capacity whitespace
Cryogenic Storage
15.8%
Other National Standards
13.4%
Advanced Therapies
12.6%
Clinical Supply Partnerships
12.6%
Digital chain of custody
Regulatory & Quality Svcs.
10.2%
Integrating custody records with CTMS gives real-time visibility across
Capacity-Based Revenue
9.5%
Biotechnology Companies
8.8%
Regulatory & quality bundling
Overall market
7.1%
Testing-to-filing agreements appeal to capital-efficient emerging
Validated, scalable cryogenic networks can capture premium pricing from cell & gene therapy sponsors.
multi-country depots.
biotech sponsors.
Regional Opportunity Map Regional Snapshot • North America: ~41% share (USD 0.85B); U.S. ≈ USD 0.70B in 2025.
● Europe ● North America · 41% ● Asia-Pacific · 10.0%
● India · 12.2% ● MEA ● Latin America
Navy = scale leader (2025 share) · Green = fastest growth (CAGR 2026–35) · Grey = driver / restraint exposure
Copyright © Next Move Strategy Consulting
• Asia-Pacific: fastest region at 10.0% CAGR; India leads countries at 12.2%. • Europe: outsourcing driver (+1.6%) alongside North America; peak-capacity constraints. • LatAm & MEA: trial globalization lifts LatAm; fragmented rules weigh on MEA & APAC.
03
COMPETITIVE SCENARIO
Capacity, certification and cryogenics decide share share Competitive Positioning Matrix
Market Positioning STRUCTURE
DIVERSIFIED TIC & LAB NETWORKS Compete on chamber capacity & regulatory
INTEGRATED LEADERS Bundled testing + ultra-low / cryo storage +
depth
regulatory — the position contracts are
Eurofins
moving toward
SGS
Eurofins & Intertek adding ultra-low-
Thermo Fisher
Charles River
Breadth of testing portfolio →
hold a significant share, with regional specialists serving niche cryogenic demand. COMPETITIVE LEVERS
Chamber capacity, regulatory
temp capacity (2026) DHL + CRYOPDP integrated cold-chain
Intertek
Moderately consolidated; profiled leaders
logistics
documentation depth and cGMP certification breadth. INNOVATION FOCUS
Cryogenic & ultra-low capacity, real-time environmental monitoring, digital chain of ST ANDALONE TESTING LABS
custody.
Narrow scope; losing ground as sponsors
SPECIALIZED STORAGE & COLD CHAIN
shift to dedicated-capacity bundles and
Compete on cryogenic infrastructure &
Cryoport BioStorage & BioServices revenue
stricter monitoring qualification
logistics integration
revenue +21% YoY; 21 commercial CGTs
Cryoport
BioLife Solutions
INVESTOR SIGNAL
CGTs supported (Mar 2026).
Alcami
Cryogenic / cold-chain specialization →
Key Strategies Capacity Expansion
M&A & Partnerships
Innovation & Footprint
• Eurofins: 3 new sites (Cary, San Diego,
• DHL Group acquired CRYOPDP from
• Cryoport MVE launched condition-
Toronto, 2025) + 300,000 sq ft Lancaster
Cryoport (Mar 2025), with a continuing
build from Q2 2026.
strategic partnership.
• Intertek Royston, UK expanded to 625,000
• Eurofins Lentilly, France reached 1,000 m²
• Logistics-sector entrants reshape cold-chain
litres (May 2026).
monitoring dry vapor shippers (2025).
incl. ultra-low storage (Aug 2026).
competition.
Key Market Players Profiled (20) Eurofins Scientific SE
SGS SA
Intertek Group plc
Thermo Fisher Scientific
Charles River Laboratories
WuXi AppTec
Labcorp Holdings
Catalent Inc.
Almac Group
Cambrex Corporation
Alcami Corporation
Pace Analytical Services
Element Materials Tech.
Frontage Laboratories
Cryoport Inc.
Medpace Holdings
NAMSA
Q Laboratories
Sharp Services
BioLife Solutions
Copyright © Next Move Strategy Consulting
04
THANK YOU
Let's shape your next move together
Thank You Connect with our analysts for in-depth segment data, competitive benchmarking and strategic guidance on the Pharmaceutical Stability & Storage Services Market.
OFFICIAL WEBSITE
CONTACT NUMBER
www.nextmsc.com
+1 857 758 5017
REPORT COVERAGE
info@nextmsc.com
9 segmentation axes · 5 regions · 20 profiled players
Click here for the complete report
Access Report →
Follow Us gen-dedup-b578c5504a46f03ae65a1531c4fef358.png
gen-dedup-d09b325625f14ce36fcff8cad682585a.png
Copyright © Next Move Strategy Consulting
gen-dedup-97cab8cfce412030032feed5ba215232.png
YouTube
gen-dedup-b40f187a3c7426f8c9de8ef097eb2885.png
gen-dedup-c2646964ab01347c67fa3922d6aef9a7.png
05